While CRP is a well-established downstream biomarker for IL-6 signaling, and the variants selected reflect higher levels of CRP and thus increased IL-6 signaling, there is little evidence for a causal effect of total CRP levels on risk of MS, in concordance with previous studies (6). The gene discussed is CRP; the disease is myeloid sarcoma.